Integration of artesunate into a cabozantinib-based therapy concept of renal cell carcinoma in vitro
Laufzeit: 01.01.2023 - 31.12.2026
imported
Kurzfassung
In the current study we investigate whether artesunate, from Traditional Chinese Medicine (TCM), simultaneously applied with the tyrosine kinase inhibitor (TKI) cabozantinib might induce additive or synergistic antitumor effects in renal cell carcinoma cells.